Summary
Economic analyses have become increasingly important in healthcare in general and with respect to pharmaceuticals in particular. If economic analyses are to play an important and useful role in the allocation of scarce healthcare resources, then such analyses must be performed properly and with care. This article outlines some of the basic principles of pharmacoeconomic analysis. Every analysis should have an explicitly stated perspective, which, unless otherwise justified, should be a societal perspective. Cost minimisation, cost-effectiveness, cost-utility and cost-benefit analyses are a family of techniques used in economic analyses. Cost minimisation analysis is appropriate when alternative therapies have identical outcomes, but differ in costs. Cost-effectiveness analysis is appropriate when alternative therapies differ in clinical effectiveness but can be examined from the same dimension of health outcome. Cost-utility analysis can be used when alternative therapies may be examined using multiple dimensions of health outcome, such as morbidity and mortality. Cost-benefit analysis requires the benefits of therapy to be described in monetary units and is not usually the technique of choice. The technique used in an analysis should be described and explicitly defended according to the problem being examined. For each technique, the method of determining costs is the same; direct, indirect, and intangible costs can be considered. The specific costs to be used depend on the analytical perspective; a societal perspective implies the use of both direct and indirect economic costs. A modelling framework such as a decision tree, influence diagram, Markov chain, or network simulation must be used to structure the analysis explicitly. Regardless of the choice of framework, all modelling assumptions should be described. The mechanism of data collection for model inputs must be detailed and defended. Models must undergo careful verification and validation procedures. Following baseline analysis of the model, further analyses should examine the role of uncertainty in model assumptions and data.
This is a preview of subscription content, access via your institution.
References
Beck JR, Pauker SG. The Markov process in medical prognosis. Medical Decision Making 3(4): 411–458, 1983
Blades CA, Culyer AJ, Walker A. Health service efficiency: appraising the appraisers — a critical review of economic appraisal in practice. Social Science in Medicine 25(5): 461–472, 1987
Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics, Harvey Whitney Books Company, Ohio, 1991
Clemen RT. Making Hard Decisions, PWS Kent, Boston, 1991
Crane VS. Economic aspects of clinical decision making: applications of clinical decision analysis. American Journal of Hospital Pharmacy 45: 548–553, 1988
Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Medical Decision Making 6(2): 85–92, 1986
Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. American Journal of Hospital Pharmacy 42: 791–802, 1985
Dittus RS, Roberts SD, Wilson JR. Quantifying uncertainty in medical decisions. Journal of the American College of Cardiology 14(3): 23A–28A, 1989
Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Medical Decision Making 5(2): 157–177, 1985
Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term ‘cost-effective’ in medicine. New England Journal of Medicine 314(4): 253–256, 1986
Drummond MF. Principles of economic appraisal in health care, Oxford University Press, Oxford, 1980
Drummond MF. Survey of cost-effectiveness and cost-benefit analyses in industrialised countries. World Health Statistical Quarterly 38(4): 383–401, 1985
Drummond MF, Stoddard GL, Labelle R, Cushman R. Health economics: An introduction for clinicians. Annals of Internal Medicine 107(1): 88–92, 1987a
Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford Medical Publications, Oxford, New York, Toronto, 1987b
Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. Journal of the American Medical Association 262(2): 2879–2886, 1989
Eisenhut RD, Dittus RS, Roberts SD, Wilson JR. Comparing averaged-out utilities of probability trees having random parameters. Society for Industrial and Applied Mathematics Journal of Scientific and Statistical Computing 12(5): 1140–1161, 1991
Evans D, Freund D, Dittus R, Robertson J, Henry D. The use of economic analysis as a basis for inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme, Commonwealth of Australia, Department of Health, Housing, and Community Services, Canberra, Australia, 1990
Feller W. An introduction to probability theory and its applications, John Wiley & Sons, New York, 1968
Froberg DG, Kane RL. Methodology for measuring health-state preferences. III. Population and context effects. Journal of Clinical Epidemiology 42(6): 585–592, 1989
Gafni A. The quality of QALYs: do QALYs measure what they at least intend to measure? Health Policy 13(1): 81–85, 1989
Gagnon JP, Osterhaus P. Proposed drug-drug cost effectiveness methodology. Drug Intelligence and Clinical Pharmacology 21: 211–216, 1987
Gramlich EM. Benefit-cost analysis of government programs, Prentice Hall, Englewood Cliffs, 1981 Guyatt G, Drummond M, Feeny D, Tugwell P, Stoddart GL, et al. Guidelines for the clinical and economic evaluation of health care technologies. Social Science and Medicine 22(4): 393–408, 1986
Henry D. Economic analysis as an aid to subsidisation decisions: the development of the Australian guideline for pharmaceuticals. Pharmacoeconomics 1(1): 54–67, 1992
Hill WL. Economic evaluation of pharmacologic therapy. Drug Intelligence and Clinical Pharmacology 20: 594–596, 1986
Hillier FS, Lieberman GJ. Introduction to operations research, Holden-Day, San Francisco, 1974
Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991
Hillman BJ, Kahan JP, Neu R, Hammons GT. Clinical trials to evaluate cost-effectiveness. Investigational Radiology 24(2): 167–171, 1989
Howard RA, Matheson JE. The principles and applications of decision analysis, Strategic Decisions Group, Menlo Park, 1984
Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1(1): 61–80, 1982
Kats BP, Hui SL. Variance estimation for medical decision analysis. Statistics in Medicine 8(2): 229–241, 1989
Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value tradeoffs, Wiley, New York, 1976
Klein RW, Dittus RS, Roberts SD. Simulation modeling and health care decision-making: an annotated bibliography, Regenstrief Institute for Health Care, Indianapolis, 1991
Law AM, Kelton WD. Simulation modeling and analysis, McGraw-Hill, New York, 1991
Lohr K (Ed.) Advances in health status assessment. Medical Care 27(3): S1–S293, 1989
Mehres A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalent. Medical Decision Making 9(2): 142–149, 1989
Oster G. Economic aspects of clinical decision making: applications in patient care. American Journal of Hospital Pharmacy 45: 543–547, 1988
Parsen E. Stochastic processes, Holden-Day, New York, 1962
Raiffa H. Decision analysis: introductory lectures on choices under uncertainty. Addison-Wesley, Reading, 1968
Roberts SD, England WL. Survey of the application of simulation to health care. Simulation Series 10 (1), Society for Computer Simulation, La Jolla, 1981
Roberts SD, Klein RW. Simulation of medical decisions: applications of SLN. Simulation 43(5): 234–241, 1984
Shepard DS, Thompson M. First principles of cost-effectiveness analysis in health. Public Health Reports 94(6): 535–543, 1979
Simpson CA, Souney PF. Calculating costs of drug therapy: a review of a decade of literature (1977–1987). Clinical Therapeutics 10(6): 616–650, 1988
Sox HC, Blatt MA, Higgins MC, Marton KI. Medical decision making, Butterworth Publishers, Boston, London, Durban, Singapore, Sydney, Toronto, Wellington, 1988
Stokey E, Sechauser R. A primer for policy analysis, Norton, New York, 1978
Torrance GW. Toward a utility theory foundation for health status index models. Health Services Research 11(4): 349–69, 1976
Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programmes. Health Services Research 7(2): 118–133, 1972
von Neumann J, Morgenstern O. Theory of games and economic behavior, John Wiley, New York, 1953
Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care, Health Administration Press, Ann Arbor, 1982
Weinstein MC. Economic assessment of medical practices and technologies. Medical Decision Making 1(4): 309–330, 1981
Weinstein MC, Fineberg HV. Clinical decision analysis, W.B. Saunders Company, Philadelphia, London, Toronto, 1980
Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296(13): 716–721, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Freund, D.A., Dittus, R.S. Principles of Pharmacoeconomic Analysis of Drug Therapy. Pharmacoeconomics 1, 20–29 (1992). https://doi.org/10.2165/00019053-199201010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199201010-00006